Biocryst Pharmaceuticals (BCRX) Equity Average (2011 - 2026)

Biocryst Pharmaceuticals has reported Equity Average for 16 years, with the latest figure at -$336.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 27.47% year-over-year to -$336.5 million; the trailing twelve-month figure through Mar 2026 stood at -$336.5 million (up 27.47% YoY), and the FY2025 full-year result was -$297.5 million, up 36.11% from the prior year.
• Equity Average for Q1 2026 stood at -$336.5 million, down from -$253.5 million in the prior quarter.
• The five-year high for Equity Average was -$135.6 million in Q1 2022, with the low at -$475.9 million in Q2 2024.
• Historically, Equity Average has averaged -$359.1 million across 5 years, with a median of -$399.8 million in 2023.
• Annual changes were most pronounced in 2022 — Equity Average sank 187.75% — and 2025, when it surged 46.32%.
• Biocryst Pharmaceuticals' Equity Average stood at -$268.6 million in 2022, then tumbled by 61.29% to -$433.3 million in 2023, then retreated by 9.0% to -$472.2 million in 2024, then surged by 46.32% to -$253.5 million in 2025, then plunged by 32.73% to -$336.5 million in 2026.
• The last three Equity Average figures came in at -$336.5 million (Q1 2026), -$253.5 million (Q4 2025), and -$404.7 million (Q3 2025), per Business Quant data.